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Abstract
Cancer is a leading cause of death in developed countries; 27 per cent of all Australian deaths are due to
cancer, with 35,000 people dying annually. Prostate cancer is the most common type of cancer amongst men
in most Western countries. Breast cancer is the most common cancer in women aged over 30 years, and causes
the highest proportion of cancer deaths in women. At present in Australia there is a debate about the public
health value of screening for prostate cancer. This paper examines the issues that must be weighed up in
reaching a conclusion to this debate, by comparing the issues in prostate cancer screening to those of
screening for breast cancer in women. Unlike breast cancer, there is no clear consensus among experts as to
whether prostate cancer screening should be provided on a population basis. Many of these experts have
developed recommendations which state, in part, that all the information should be presented to the patient
by the physician and that the patient should make the final decision. However, if the experts cannot decide,
this leaves the layman in a rather difficult position in making an informed decision. At present, there is
insufficient evidence to conclusively determine the value of prostate cancer screening on population basis.
Health promotion practitioners are often responsible for educating and advising men as to the necessity for
cancer screening. We need to be aware that, at this point in time, there is insufficient evidence to justify
prostate cancer screening. Until further research has been undertaken to better understand the natural history
of prostate cancer, improved diagnostic procedures have been developed, risk and protective factors have been
determined, and treatment for prostate cancer conclusively shown to extend life-expectancy, we should be not
be advising men to undergo prostate cancer screening, with the possible exception of individuals who are at a
high-risk of developing the disease. Some experts describe screening for prostate cancer, while waiting for
(trial) results, as rational, appropriate, economical, and ethical, while other authorities describe screening
without better evidence of effectiveness as unconscionable, costly, self-serving, and unethical.
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SAbstractCancer is a leading cause of death in developed countries; 27 per
cent of all Australian deaths are due to cancer, with 35,000
people dying annually. Prostate cancer is the most common type
of cancer amongst men in most Western countries. Breast cancer
is the most common cancer in women aged over 30 years, and
causes the highest proportion of cancer deaths in women. 
At present in Australia there is a debate about the public health
value of screening for prostate cancer. This paper examines the
issues that must be weighed up in reaching a conclusion to this
debate, by comparing the issues in prostate cancer screening
to those of screening for breast cancer in women. Unlike breast
cancer, there is no clear consensus among experts as to
whether prostate cancer screening should be provided on a
population basis. Many of these experts have developed
recommendations which state, in part, that all the information
should be presented to the patient by the physician and that
the patient should make the final decision. However, if the
experts cannot decide, this leaves the layman in a rather
difficult position in making an “informed” decision. 
At present, there is insufficient evidence to conclusively
determine the value of prostate cancer screening on
population basis. Health promotion practitioners are often
responsible for educating and advising men as to the necessity
for cancer screening. We need to be aware that, at this point
in time, there is insufficient evidence to justify prostate cancer
screening. Until further research has been undertaken to better
understand the natural history of prostate cancer, improved
diagnostic procedures have been developed, risk and
protective factors have been determined, and treatment for
prostate cancer conclusively shown to extend life-expectancy,
we should be not be advising men to undergo prostate cancer
screening, with the possible exception of individuals who are at
a high-risk of developing the disease.
“Some experts describe screening for prostate cancer, while
waiting for (trial) results, as ‘rational’, ‘appropriate’,
‘economical’, and ‘ethical’, while other authorities describe
screening without better evidence of effectiveness as
‘unconscionable’, ‘costly’, ‘self-serving’, and ‘unethical’.”1
Primary prevention – The case for 
(and against) screening for cancer
There are several generally accepted prerequisites for a
screening program2. These prerequisites fall into two categories
– aspects of the disease and aspects of the test.
Characteristics of the disease:
n the disease should have serious consequences for the
total population (ie should cause mortality or severe
morbidity, and should affect members of the target
population);
n the disease should have a recognisable, detectable, pre-
clinical phase (DPCP) which is reasonably prevalent
amongst the target population; and
n there should be available a treatment which is more
effective if commenced during the screen-detected stage
rather than after the appearance of symptoms. For
example, both breast cancer and cervical cancer have
considerably higher survival rates if detected and treated
prior to the appearance of symptoms.
Characteristics of the test:
n suitable for detecting the disease and acceptable to the
target population;
n high sensitivity (ie a high proportion of tested persons
who have the DPCP should test positive), high specificity
(ie a high proportion of tested persons who do not have
the DPCP should test negative), and high positive
predictive value (ie high probability of cancer when the
test is positive);
n the costs of applying the test on a population basis
should be economically viable; and
n the test should not itself cause morbidity or mortality.
Gender-specific cancers – breast and prostate
Cancer is a leading cause of death in developed countries. In
Australia cancer kills more people than heart disease,
cerebrovascular disease, or respiratory disease. Twenty-seven
percent of all Australian deaths are due to cancer, with 35,000
people dying annually. 
Prostate cancer and prostate cancer
screening
Prostate cancer is the most common type of cancer amongst
men in most Western countries. Prostate cancer begins in the
prostate gland, but may spread to nearby lymph glands, bones,
bladder, rectal, and other areas. Generally, early prostate
cancer does not cause detectable symptoms; however, the
symptoms (such as frequent urination, painful urination and
painful ejaculation), when they do occur, are very similar to the
symptoms of benign prostatic hyperplasia. Prostate cancer
incidence is strongly associated with age, increasingly
considerably after the age of 50 years.
As with breast cancer, there are two main methods of
screening for prostate cancer. The traditional test, the digital
rectal examination, consists of the doctor inserting a finger into
the rectum and palpating the prostate gland. The “scientific”
screening procedure is a blood test to determine the level of
prostate-specific antigen in a blood strain; the level of PSA may
rise in men with prostate cancer, benign prostatic hyperplasia,
or some other infections.
Screening for Prostate Cancer: A Consideration 
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Breast cancer and breast cancer screening
Breast cancer is the most common cancer in women aged over
30 years(1), and also causes the highest proportion of cancer
deaths. Age is the single biggest risk factor for breast cancer3.
It has long been known that, if detected and treated early
enough, breast cancer sufferers have a high survival rate; and
that screening and early treatment are effective tools in
increasing breast cancer survival rates. 
Screening for breast cancer consists of two separate, and quite
different, strategies. The first, and most comprehensively
investigated, method of screening for breast cancer is by
mammography. The second method of screening for breast
cancer is clinical breast examination. For the purposes of this
paper, clinical breast examination can be likened to DRE, and
mammography to prostate-specific antigen screening.
Characteristics of the disease:
n The disease should have serious consequences for the total
population (ie should cause mortality or severe morbidity,
and should affect members of the total population)
Prostate cancer
Prostate cancer is the most common cancer diagnosed in men
in Australia, as in most Western countries, and both incidence
and mortality are rising4. In the United States, for example, it is
estimated that 40,000 men died from prostate cancer in 1995.
In the US as in Australia, prostate cancer is now the most
commonly diagnosed cancer among menv.
Breast cancer
Breast cancer is the most common cancer in women aged over
30 years. Over the last seven years, incidence rates have
increased in Australia, due to an aging population and
increases in mammographic screening, whilst mortality rates
have been declining at around 3% per year6. Age is the single
biggest risk factor for breast cancer4, with incidence rates
increasing progressively from the age of 306.
Comparison between prostate cancer and
breast cancer
In 1996, 9,621 new cases of breast cancer were diagnosed in
Australia, and 2,619 women died from the disease, equating
to 30,955 person years of life lost (PYLL). In the same year,
10,055 new cases of prostate cancer were diagnosed in
Australia, and 2,644 men died from the disease, equating to
6,228 person years of life lost (PYLL).6
n The disease should have a recognisable, detectable, pre-
clinical phase which is reasonably prevalent amongst the
target population
Prostate cancer
Prostate cancer does have a recognisable, detectable,
preclinical phase that is prevalent in the population; in fact,
some studies show that prevalence of histologic evidence of
prostate cancer is as high as 42% at age 50-59, 58% at age
60-69, 66% at age 70-79, and 100% at age 80 and older7.
However, screening cannot at this time differentiate between
aggressive (and thus life-threatening) cancers and less
aggressive ones (that will not lead to mortality or morbidity in
the individual). Research shows that up to 30% of men over
the age of 30 who are autopsied have detectable, if
microscopic, prostate cancers. However, the risk of death from
prostate cancer under the age of 75 is one in 708. According to
available statistics, the US Department of Health and Human
Services estimates that millions of American men have prostate
cancer, though less than 40,000 will die of the disease
annually. This suggests that “only a subset of cancers in the
population are clinically significant and that widespread
screening is likely to detect a large proportion of cancers whose
effect on future morbidity and mortality is uncertain”9. They
further conclude that it is not yet known whether PSA will
identify aggressive cancers at the stage where they are still
potentially curable.
Breast cancer
Breast cancer also has a recognisable, detectable, preclinical
phase, and studies show that “moderate” reductions in
mortality between 20 – 30% can be expected.9 Breast
screening aims to detect small cancers, ideally less than 1cm.
Small cancers are less likely than larger tumours to have
metastasised and are generally regarded as constituting early-
stage disease10. 
However, it is important to note that mammographic screening
also detects ductal carcinoma in situ (DCIS). Currently in
Australia, approximately 10-20% of breast cancers detected by
mammographic screening are DCIS11,14,13. DCIS is a non-invasive
variant of breast cancer which involves abnormal growth of the
cells lining the ducts in the breast which, by definition, has not
spread beyond the ducts12,13,14. The natural history of DCIS and
its link with invasive breast cancer is not well understoodxv. As
with prostate cancer, “the most innocuous, low-grade looking
forms of DCIS may never cause a clinical problem if left
untreated”13. However, it has been estimated that 20-25% of
DCIS lesions will progress to invasive breast cancer13,15, and
women with DCIS are more likely to develop breast cancer in
the future. Invasive cancer recurrence rates are significantly
reduced by treatment of the DCIS with mastectomy or
conservative surgery with radiotherapy15.
n There should be available a treatment which is more
effective if commenced during the screen-detected stage
rather than after the appearance of symptoms
Prostate cancer
There is considerable debate as to whether early detection of
prostate cancer has any impact on survival. A large scale trial,
commenced in 1992, is being undertaken by the National
Cancer Institute (NCI) in the United States; 74,000 men will be
randomly allocated to either annual screening for prostate
cancer or no screening16. This is a long-term study, and
conclusive results will not be available for several years6.
In the meantime, some researchers believe that radical
prostatectomy is an effective treatment for screen-detected
prostate cancer5. A study at the University of Quebec reported:
“137 deaths due to prostate cancer occurred in the 38,056
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(1) Whilst it is acknowledged that men can, and do, develop breast cancer, the incidence in males is extremely low; thus breast cancer is generally (and for
the purposes of this paper) considered to be a female disease.
Photograph courtesy of Curtin University of Technology Perth WA
the 8,137 screened men ... or a 69% decrease in the deaths
from prostate cancer in the group of men who were screened
and received early treatment”17. Subsequently, the same author
reported on five randomised studies of hormone therapy for
screen-detected prostate cancer and concluded that “simple
use of the available screening procedures and treatment for
localised prostate cancer could cause a dramatic decrease in
prostate cancer death”18.
Other researchers, however, question the efficacy of prostate
screening. For example, CCIHF state that “there is no
information yet available that can tell us whether screening for
prostate cancer makes any difference whatsoever to how long
the patient will live after his prostate cancer is discovered”19.
Gohagan criticised the 1998 Labrie study outlined above, as
follows: “Of the entire group of men in Labrie’s study, 31,000
were invited to come in for PSA screening, but only 7,100
showed up. Instead of sticking to the “randomisation” part of
the process, anyone who didn’t show up was put into the
“unscreened” pile. And during the first round of screening,
men whose test indicated that they already had cancer were
also dumped into the unscreened category... Counting men
that way skewed the data, making the unscreened group look
like cancer magnets”20.
Despite the earlier quoted figure that as many as 30% of men
in their thirties have prostate cancer, the risk of death from the
disease under the age of 75 is one in 7010. Additionally,
autopsies of older men show that up to one-third have
undiagnosed prostate cancer (which was not the cause of
death) and two-thirds of men who have been diagnosed with
prostate cancer will die from other causes21. In Chapman’s
words “there are many men walking about today with the
‘sleeping dog’ of prostate cancer. For many, this dog will never
wake up and deliver a serious or lethal bite”19. 
The US Department of Health and Human Services9 cautions
that, as the extent of lead-time and length biases are currently
unknown, and as it is difficult to differentiate between
aggressive and indolent prostate cancers, it is not possible to
determine whether many patients who have undergone radical
prostatectomy would have survived just as long without
treatment.
The debate is perhaps best summed up in the following 
two quotes (from the prostate cancer website –
http://www.prostatepointers.org/ww/toscreen.htm):
“Since Prostate Cancer Awareness Week began in 1989, more
than 3 million men have been screened. In numerous cases,
screening save lives by detecting the disease in its earliest,
most critical stages” (Prostate Cancer Education Council).
“It does not seem appropriate that we simply screen men or
launch free screening programs, with the implied promise of
benefit. This would deviate from the Hippocratic principle of
‘first do no harm’.” (National Cancer Institute)
The greatest “harm” comes not from the screening test itself,
but from the diagnostic and treatment procedures which
follow a positive diagnosis. Some of the possible consequences
of these procedures include9:
n needle biopsy – the confirmatory diagnostic procedure – is
relatively safe, although it results in infection, septicemia,
and/or significant bleeding in a small percentage of
patients (note that this is a similar procedure to the
confirmatory diagnostic needle biopsy used to (dis)confirm
suspected breast cancers detected by mammography);
n radiation therapy has been estimated to have a risk of
death between 0.2-0.5%, gastrointestinal and
genitourinary complications in 8-43% of patients, chronic
complications in 2 %, impotence in 40-67%, urethral
stricture in 3-8%, and incontinence in 1-2%9; 
n hormone therapy – to reduce, or eliminate, the
production of male hormones – has side-effects which
can include decrease in sexual desire, impotence, hot
flushes, nausea, vomiting, tenderness and swelling22; and
n radical prostatectomy – the surgical treatment for prostate
cancer – has significant side-effects. Estimates of
operative mortality range from 0.7-2%, of impotence
from 20-85%, incontinence from 2-27%, urethral
stricture from 10-18%, thromboembolism 10%, and
permanent rectal injuries 3%. In practical terms, some of
these effects include 30% of post-operative men wearing
pads to control wetting, 6 % undergoing corrective
surgery for incontinence, 2% requiring a catheter, 60%
reporting partial erections, 15% requiring treatment for
sexual dysfunction, and 20% requiring dilatations or
surgical procedure for strictures9.
Breast cancer
The value of mammographic screening in reducing breast
cancer mortality and morbidity has been investigated and
proven over many years. Population-based screening was
introduced in many countries, including Australia, as a result of
many long-term studies which demonstrated that many breast
cancers detected in the preclinical phase could be successfully
treated23. It is generally accepted that mammographic
screening on a population basis results in a reduction in breast
cancer mortality of around 30% 21,24. 
The one caveat to this benefit is that it is age-related, with the
greatest benefits for women aged over 50 years4, 11. There is
some benefit in screening women under 50; however, due to
the increased number of false positives it is not (as) cost
effective and there is considerable psychological impact. 
Breast self-examination, on the other hand, can clearly only
detect symptomatic cancers (although at an earlier stage than
they would otherwise be discovered), and has not been shown
to reduce mortality11.
As with prostate cancer, there are considerable side-effects of
treatment for breast cancer. These include:
n surgery – scarring and disfigurement (although this is less
so with new surgical techniques, particularly breast-
conserving operations), need for further reconstructive
surgery in the case of mastectomy, risk of infection,
reduced sensitivity due to nerve damage, swelling of the
arm (lymphoedema); and
n radiotherapy – general tiredness, some reddening or
‘sunburning’ of the skin, and the breast may change a
little in size or shape or feel different in texture.
n However, it is important to note that, in the case of breast
cancer, these negative effects are the result of a
procedure which has been conclusively demonstrated to
reduce mortality and increase life expectancy25.
Comparison between prostate cancer
screening and breast cancer screening
It is argued by many that prostate cancer is unlike breast cancer
in that screening for the latter has long been demonstrated to
reduce mortality and increase survival subsequent to the onset
of the disease17. However, in relation to prostate cancer, it has
been estimated that when quality-of-life adjustments are
incorporated, “one-time screening of men aged 50-70 would
increase life expectancy by 0-0.2 days and 0.6-1.6 days,
respectively, but quality-adjusted life would be decreased by









1.8-7.1 days and 2.1-9.5 days, respectively, per patient
screened”26.
Further, it is posited “that using the PSA test for detecting
prostate cancer in asymptomatic men is not analogous to
mammography for early detection of breast cancer in
asymptomatic women. Apart from the unproven benefit, there
is a need for universally applied guidelines for the management
of men with an abnormal test result, parallel to those built into
the mammographic screening program” 27(p 9). 
It is also suggested that, unlike breast cancer, the greatest
benefits of screening are not for those in older age groups. The
American College of Physicians6 estimates that population
screening of men over the age of 69 years will result in increased
life expectancy of only a few days, and studies show that the 
10-year survival rate for early-stage prostate cancer approaches
90%9 (p 8). Thus, the recommendations of many expert bodies
include not screening men over the age of 70. 
Characteristics of the test:
n The test to be suitable for detecting the disease and
acceptable to the target population
Prostate cancer screening
The traditional, and most well-known, method of screening for
prostate cancer is by digital rectal examination. This test, whilst
there is a lack of evidence from controlled studies to
demonstrate its effectiveness in reducing cancer mortality, has
few disbenefits6; it has no significant immediate risks, requires
little time, and, as it is usually performed as part of a regular
check-up, does not incur extra financial cost. 
The newer and more “scientific” screening test is prostate
specific antigen (PSA) testing. It is generally accepted that a
level greater than 4.0ng/mL is clinically suspicious and worthy
of follow-up6. However, there is considerable debate as to the
use of age-specific PSA thresholds (see, for example,
Oesterling, 1996). Anecdotal evidence suggests that, for many
men, PSA may be a preferable screening test to DRE as it is a
less physically and psychologically invasive procedure.
Breast cancer screening
Breast cancer screening is generally accepted by both the
target population and the medical profession as a valuable
preventive behaviour. A 1991 population survey28 found that
78% of Australian women have conducted self-checks of their
breasts, although only 23% conduct the recommended
monthly self-examination. Similarly, the 1996 Breast Health
Survey29, a survey of 3,000 Australian women aged 30–69
years found that 93% of women reported doing BSE at least
once, but only 37% of those surveyed reported practising BSE
monthly. Mammographic screening rates in NSW have
increased steadily since 1984, with an estimated 72% of
women in their 50s and 67% in their 60s having had at least
one mammogram30. Australia’s population breast screening
program – Breast Screen – commenced in 1991. Acceptance of
the use of mammographic screening as a preventive tool for
breast cancer is evidenced in target group surveys which show
that women believe the benefits outweigh the risks31; high
participation rates – approximately 70% of eligible Australian
women(2); and high rescreening levels21. Several studies have
shown that breast cancer mortality could be further reduced by
increasing compliance with screening recommendations32,33.
n The test should have high sensitivity, specificity, and
positive predictive value
Prostate cancer screening
In discussing the accuracy of prostate cancer screening tests, it
is important to bear in mind the following caveat: “the
sensitivity and specificity of screening tests for prostate cancer
cannot be determined with certainty, however, because
biopsies are generally not performed on patients with negative
screening test results”9. Thus, the following discussion will rely
on widely varying estimates of sensitivity, specificity, and
positive predictive value.
Whilst the DRE may have high acceptance, it does not appear
to have either high sensitivity or high specificity. The US
Department of Health reports, from a review of numerous
studies, that DRE has a sensitivity of 55-68 %, although it can
be as low as 18-22% using different screening protocols; and
limited specificity, which results in a high proportion of false-
positive results9. The American College of Physicians estimates
that the positive predictive value is in the region of 15-30%
and concludes that the negative predictive value is considerably
lower (ie a negative digital rectal examination does not
substantially decrease the odds of a subsequent prostate
cancer)6. The US Department of Health9 reports that positive
predictive value in asymptomatic men tends to be higher when
the test is performed by urologists rather than physicians.
Again, there is considerable debate as to the effectiveness of
prostate-specific antigen testing; with some investigators
reporting the test to have high sensitivity and high specificity5.
In fact, Gann, Hennekens & Stamorer go so far as to say, “PSA
has the highest validity of any circulating cancer screening
marker discovered thus far”34. Other researchers, however,
report that, whilst PSA may have high sensitivity (over 80%), the
specificity is much lower (as low as 29%), depending on the
screening protocols9. The sensitivity of the test, as would appear
intuitively logical, increases as the level of PSA increases; an
approximate positive predictive value of 20% for levels between
4-10 increases to 42-64% for levels greater than 10 ng/mL6.
Conversely, the specificity of PSA testing decreases with
increasing age; this is due to the age-related development of
benign prostatic hyperplasia6. It is estimated that 50% of US
men aged between 60 and 70 have benign prostatic
hyperplasia (BPH), and as many as 90% of those aged 80 to 90
have this condition19. Additionally, the American College of
Physicians state that “no published studies of PSA measurement
in unselected populations have applied an acceptable reference
standard ... the true sensitivity and specificity of PSA
measurement are unknown”6. As Burton35 points out, serum
PSA is the first proposed population screening test that has a
continuous range; all other currently used tests (such as Pap
smear, screening mammogram and faecal occult blood test)
have dichotomous results – positive vs negative.
Two other methods for detecting prostate cancer, transrectal
ultrasonography and transrectal needle biopsy, are not
intended as screening tests.
Breast cancer screening
Mammography is able to detect breast cancer in seven out of
10 women in whom disease is present36. Around 93% of
women without the disease can be excluded from further
assessment following the initial screen. These data suggest that
the test has reasonable sensitivity and specificity. It is the best
available technique for the early detection of breast cancer12.
Additionally, some indication of the sensitivity of
mammographic screening can be found in studies of
subsequent interval cancers. For example, a study of the
incidence of interval breast cancers in the 12 months following
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(2) This figure is lower than that quoted in many other studies (eg Glasziou & Irwig, 1997), but it is noted that many of these studies are based on reported
compliance.
was acceptable and should result in a significant mortality
reduction in the screened population”37.
n The costs of applying the test on population basis should
be economically viable
Whilst, in an ideal world, economic factors would not be a part of
decisions as to whether to screen for potentially fatal diseases, the
reality of opportunity cost means that all potential interventions
must be considered in the light of the ratio of benefits to costs:
“resources are scarce, requiring choices to be made about what
health care to provide and what not to provide”38.
Prostate cancer screening
It has been estimated that, if every eligible man in the US
decided to undergo annual prostate cancer screening it would
cost several million dollars per year16. More specifically,
Waldman & Osborne estimate that if all men between the ages
of 50 and 70 in the US were screened for prostate cancer the
cost would come to in excess of $15 billion (if suspect PSA level
were set at 10 ng/mL) or $27.9 billion (if set at 4ng/mL), plus
an additional $23.6 billion for confirmatory transrectal
ultrasonography39. The benefits of screening are not proven,
making the benefit:cost ratio for prostate cancer screening
prohibitive. An economic evaluation of potential prostate
cancer screening program in France concluded that mass
screening should not be recommendedxl. The US Department
of Health and Human Services concurs that, without significant
improvements in diagnosis and treatment, a population
screening program would not be cost-effective. Further, given
a 10-year survival rate of 90% for early-stage prostatic cancer,
they recommend against screening of men aged over 70 on
both economic and quality of life grounds7. Similarly, the
American College of Physicians5 suggests that the highest
comparative benefit from screening would be obtained for
men aged 50 to 69 years, although they still recommend
against population screening. 
Breast cancer screening
The costs of breast cancer screening are also very high;
however, these costs are weighed up against the reduction in
costs (both financial and social) from detecting and treating a
cancer which has been clearly demonstrated to be often curable
in its early stages. It is important to note that, on currently
available evidence, the public health and economic benefits are
gained from population screening of women aged 50-69. The
benefit of screening women aged 40-49 on a population basis
is currently the subject of considerable debate33.
n The test should not cause morbidity or mortality
Prostate cancer screening
Although there are no immediate risks from PSA testing, other
than those usually incurred from any blood-test, it is posited that
there are a number of subsequent risks which are not countered
by demonstrable benefits. For example, many false-positive
testees will then suffer the discomfort of a subsequent,
unnecessary, needle biopsy. The greatest risk, however, is for
those false positives who undergo radical treatment for
presumed prostate cancer with its subsequent significant
negative side-effects. This also applies to true positives whose
prostate cancer would not have led to their death before they
died of other causes. These negative effects are discussed above.
Breast cancer screening
A mammogram is a form of x-ray which uses a very low dose of
radiation. The benefit of screening far outweighs the risk of any
harm from the x-ray41. Possible disbenefits of screening include:
fear and anxiety associated with screening and assessment;
false reassurance for women with false negative results; for
women with incurable breast cancers, they will spend a longer
time with the knowledge that they have the disease; the
possibility of unnecessary diagnostic tests and associated
morbidity for women with false positive results; lesions which
might otherwise have regressed may be detected through
screening and treated unnecessarily; and there may be a small
radiation risk associated with the test itself12. It should be noted
that all of these, with the exception of the last (radiation), apply
equally to prostate cancer screening. The side-effects of breast
cancer treatment are also discussed above.
So what do the experts think?
Prostate cancer screening
As discussed above, there is considerable debate as to the
value of population screening for prostate cancer. This debate,
and the current balance of opinion against screening – at least
until further evidence is available – is reflected in the division
between the minority of expert bodies who recommend
population screening for prostate cancer, and the majority
(including The Cancer Council Australia, American Cancer
Society, International Union Against Cancer and World Health
Organisation) who recommend against it. The general
consensus is that the potential benefits and known harms of
screening, diagnosis, and treatment should be explained to the
individual patient who would then make their own decision as
to whether to undergo screening.
Breast cancer screening
There is no such division in relation to population breast cancer
screening, with a consensus view that regular mammographic
screening be provided to all women over the age of 50(3).
Conclusions
At present, there is insufficient evidence to conclusively
determine the value of prostate cancer screening on a
population basis. There are many issues and questions which
must be resolved. For example, the natural history of prostate
cancer needs to be better understood, and diagnostic
procedures refined, in order to differentiate between
aggressive (and thus life-threatening) tumours and latent (and
thus not life-threatening) tumours. Similarly, it remains to be
determined conclusively if, and by how much, current
treatment for prostate cancer extends life-expectancy of men
with even aggressive forms of this disease. Any analysis of this
issue would need to take into account the negative
consequences of treatment and subsequent quality of life
issues. Related to this, there is the need for specific guidelines
for clinicians on PSA reference ranges and velocity (ie the
changes in PSA over time), including decisive guidelines on the
value and use of age-specific reference ranges42.
So what should the layman do? Many of the “experts” quoted
above have developed recommendations which state, in part,
that all the information should be presented to the patient by
the physician and that the patient should make the final
decision in their own case. Whilst this may have the advantage
of removing the burden of responsibility from the physician
and/or the advisory body, it transfers this thorny problem to the
patient. In the words of Wolfe & Wolfe: “when professional and
government organisations cannot agree on the standard for
screening for this prodigious disease, how can lay individuals be
expected to decide when to be screened or tested?”43.
It is important to bear in mind that the predominantly negative
assessment of prostate cancer screening is based on current
techniques (screening, diagnostic and treatment). Advances in
any, or all, of these techniques in the future may well lead to a









(3) At the present time, however, there is an unresolved debate as to the value of screening younger women.
shift towards population screening. For example, the American
Association for Cancer Research are working on a new approach
to detection, based on the testing of urine to detect an early
genetic change which occurs in 90% of prostate cancers44. n
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